jeudi 12 décembre 2019

Onco Actu du 12 décembre 2019


1. BIOLOGIE



Mechanism reprograms breast cancer to become metastatic [Baylor College of Medicine]











Study Reveals Mechanisms That Help Pancreatic Cancer Cells Avert Starvation [NYU Langone]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Three months later, the Trump administration's vaping policy is yet to be seen [CNN]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Project GENIE Contributes Data on More Than 40,000 New Cancer Cases [Cancer Research Catalyst]











5.10 TRAITEMENTS - ESSAIS



Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3 [Novartis]











Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer [Lilly]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



Look Beyond Molecular Testing to Predict Response to Immunotherapy Agents, Study Says [Dana-Farber Cancer Institute]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Novartis still hasn't solved its CAR-T manufacturing issues [Biopharma Dive]










5.4 TRAITEMENTS - ECONOMIE



Arguments on Drug Pricing [In The Pipeline]











Targeted ovarian cancer drug made available to more people on NHS in England [Cancer Research UK]











Venturing A Perspective On The Drug Pricing Debate [Life Sci VC]










5.7.2 SABCS-DIVERS



SABCS: Pfizer's Ibrance backs up benefit in HER2-negative breast cancer with real-world data [Fierce Pharma]











5.7.4 SABCS-ESSAIS



Combining Endocrine Therapy with a CDK4/6 Inhibitor Results In Similar Response Rates to Chemotherapy for High-Risk Luminal B Breast Cancer [SABCS]











Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer [SABCS]











New drugs show rare promise against advanced breast cancer [AP]











5.7.4.1 SABCS-ESSAIS-TUCATINIB



SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data [Fierce Biotech]










Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine [Seattle Genetics]











Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients [MD Anderson Cancer Center]











5.7.4.2 SABCS-ESSAIS-TRASTUZUMAB DERUXTECAN



SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months [Fierce Biotech]











Targeted Drug Shows Promise Against HER2-Positive Breast Cancer That Stops Responding to Other Drugs [Memorial Sloan Kettering Cancer Center]











SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance [Vantage]










Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial [AstraZeneca]











AstraZeneca-Daiichi drug halts cancer for months in first readout [Reuters]











What does $6.9B buy these days in oncology R&D? AstraZeneca has a landmark answer [EndPoints]











New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1 [SABCS]











5.7.4.3 SABCS-ESSAIS-PERTUZUMAB



SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis [Fierce Pharma]










APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen [Roche]











Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer [Roche]











Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer [SABCS]











5.7.4.4 SABCS-ESSAIS-MARGETUXIMAB



MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium [MacroGenics]











SABCS: MacroGenics' margetuximab posts OS gains in specific metastatic breast cancer patients [Fierce Biotech]











5.8.3 ASH - DIVERS



At ASH, Researchers Discuss Rapid AML Nanopore Sequencing Assay for Analyzing Actionable Alterations [Genome Web]











5.8.6 ASH - LEUCÉMIES



Bristol-Myers shows off a low-profile AML contender it gained from Celgene buyout — and they’re taking it straight to the FDA [EndPoints]











6.6 PUBLICATIONS



Predatory journals: no definition, no defence [Nature]